AstraZeneca PLC

AZN

GB0009895292

Pharmaceuticals

Market Closed - London S.E. Other stock markets 16:35:26 13/09/2024 BST			5-day change	1st Jan Change
11,928.00 ^GBX	-1.01%		-5.71%	+12.53%

09-13	AstraZeneca, Daiichi Sankyo Breast Cancer Drug Trial Shows 'Substantial Clinical Activity'	MT
09-13	Daiichi, Astra's Enhertu shows clinical activity in brain metastases	AN

ASTRAZENECA : DZ Bank remains Neutral

July 26, 2024 at 02:17 pm

DZ Bank confirms his opinion on the stock and remains Neutral.

Latest news about AstraZeneca PLC

AstraZeneca, Daiichi Sankyo Breast Cancer Drug Trial Shows 'Substantial Clinical Activity'	09-13	MT
Daiichi, Astra's Enhertu shows clinical activity in brain metastases	09-13	AN
Stocks up as market raises bets on bumper US cut	09-13	AN
AstraZeneca, Daiichi Sankyo Reports Safety Profile of Breast Cancer Drug in Phase 3b/4 Study	09-13	MT
Daiichi Sankyo Company Limited and Astrazeneca Announces Enhertu Showed Substantial Clinical Activity in Patients with Her2 Positive Metastatic Breast Cancer and Brain Metastases	09-13	CI
A central bank and it's off again?	09-13
Deutsche Bank Downgrades AstraZeneca to Sell From Hold	09-13	MT
ASTRAZENECA : Deutsche Bank upgrades to 'sell'.	09-13	CF
Deutsche Bank Downgrades AstraZeneca to Sell, Trims PT	09-13	MT
Gold miners shine but AstraZeneca curbs progress	09-13	AN
AstraZeneca downgraded by Deutsche Bank	09-13	CF
ASTRAZENECA : Deutsche Bank downgrades from Neutral to Sell	09-13	ZD
Deutsche Bank cuts AstraZeneca to 'sell'	09-13	AN
Stocks rise and gold gleams as eyes turn to Fed	09-13	AN
European shares climb with focus on US cenbank policy decision	09-13	RE
UK scrutiny for Vodafone-Three; Flutter in Brazil bet	09-13	AN
European Equities Traded in the US as American Depositary Receipts Flat in Thursday Trading	09-12	MT
Bioinvent International AB Announces the Enrollment of the First Patient in Triple Combination Arm of Phase 1/2A Study, Bi-1206, Rituximab and Calquence(R) for the Treatment of Non-Hodgkin's Lymphoma	09-12	CI
AlphaValue/Baader Europe Upgrades AstraZeneca to Add, Lifts PT	09-11	MT
Nordea Bank Downgrades AstraZeneca to Sell	09-11	MT
The mood is getting heavier, but Taylor Swift is keeping watch	09-11
FTSE 100 in uninspiring gain before US data	09-11	AN
ASTRAZENECA : Set to conquer new highs backed by ambitious goals	09-11
AstraZeneca 'Working Very Closely' With Chinese Authorities on Probe, CEO Tells Bloomberg	09-10	MT
European Equities Close Lower in Tuesday Trading; Apple, Google Lose Appeals Against European Commission	09-10	MT

AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows: - product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases); - collaboration revenue (4.4%). Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).

Employees

89,900

Sector

Pharmaceuticals

Calendar

08:10am - European Society for Medical Oncology Meeting - Abstract No #LBA22

More about the company